Coherus BioSciences (CHRS) stock price, revenue, and financials

Coherus BioSciences market cap is $1.1 b, and annual revenue was $356.07 m in FY 2019

$1.1 B

CHRS Mkt cap, 27-Mar-2020

$356.1 M

Coherus BioSciences Revenue FY, 2019
Coherus BioSciences Net income (FY, 2019)89.8 M
Coherus BioSciences EBIT (FY, 2019)107.8 M
Coherus BioSciences Cash, 31-Dec-2019177.7 M
Coherus BioSciences EV980.9 M

Coherus BioSciences Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

31.1m30.0m190.1m1.6m356.1m

Revenue growth, %

(3%)533%

R&D expense

78.2m213.1m254.4m162.4m110.2m94.2m

General and administrative expense

17.6m36.0m51.6m71.3m94.2m137.0m

Operating expense total

95.8m249.1m306.0m233.7m204.4m231.2m

EBIT

(64.7m)(219.1m)(115.9m)(232.1m)(204.4m)107.8m

EBIT margin, %

(208%)(729%)(61%)(14919%)30%

Pre tax profit

92.8m

Income tax expense

2.9m

Net Income

(87.1m)(223.3m)(127.3m)(238.2m)(209.3m)89.8m

Coherus BioSciences Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

150.4m158.2m124.9m126.9m72.4m177.7m

Accounts Receivable

142.0m

Prepaid Expenses

18.4m83.0k5.0m

Inventories

1.9m1.7m9.8m

Current Assets

179.1m197.4m161.5m145.5m84.4m343.0m

PP&E

4.5m10.5m10.8m12.8m6.7m5.8m

Goodwill

943.0k943.0k943.0k943.0k943.0k943.0k

Total Assets

187.2m212.4m178.5m162.6m99.5m408.9m

Accounts Payable

8.8m25.9m19.7m15.5m15.3m26.0m

Current Liabilities

51.8m106.0m56.4m28.4m33.3m115.0m

Long-term debt

10.3m

Total Debt

10.3m

Total Liabilities

159.1m132.1m138.1m303.7m

Common Stock

6.0k7.0k7.0k

Additional Paid-in Capital

254.0m404.2m558.5m808.1m946.5m1.0b

Retained Earnings

(186.7m)(410.0m)(537.3m)(775.5m)(984.8m)(895.0m)

Total Equity

66.8m(6.9m)19.4m30.5m(38.6m)105.2m

Financial Leverage

2.8 x-30.7 x9.2 x5.3 x-2.6 x3.9 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

100.9m115.1m206.1m153.7m179.6m220.9m159.7m124.9m73.4m135.6m82.0m130.0m101.2m81.5m105.9m165.1m

Accounts Receivable

2.0m1.5m540.0k1.2m419.0k419.0k26.0k46.5m77.4m89.6m

Prepaid Expenses

18.0m20.1m27.0m31.7m26.0m15.0m16.6m30.5m34.2m21.1m32.0k145.0k179.0k5.6m5.2m3.1m

Inventories

2.3m4.3m7.7m

Current Assets

118.9m143.9m239.6m189.3m211.6m236.8m177.3m208.3m153.3m171.6m112.2m172.8m130.3m159.2m205.6m276.4m

PP&E

3.7m5.1m6.3m8.7m10.3m9.9m10.7m14.9m14.5m13.8m11.9m11.2m6.8m6.1m5.6m5.9m

Goodwill

943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k

Total Assets

129.2m153.2m249.5m202.3m226.2m251.1m192.4m227.5m172.3m189.8m128.5m188.3m141.5m186.1m240.5m327.4m

Accounts Payable

4.4m10.9m14.1m25.2m17.9m17.4m22.9m12.6m15.8m10.1m14.3m13.3m7.6m11.2m19.2m13.7m

Current Liabilities

48.1m51.9m69.9m82.5m92.9m108.3m58.4m47.3m35.9m31.4m27.6m22.2m24.5m41.4m61.2m82.7m

Long-term debt

79.7m79.3m10.8m

Total Debt

79.7m79.3m10.8m

Total Liabilities

120.0m115.2m153.2m162.3m293.1m313.0m160.6m150.5m141.4m134.9m131.6m126.5m129.1m224.6m244.4m271.4m

Common Stock

1.0k3.0k4.0k4.0k4.0k4.0k4.0k5.0k5.0k6.0k6.0k7.0k7.0k7.0k7.0k7.0k

Additional Paid-in Capital

5.9m266.2m383.5m398.6m409.8m485.0m494.8m691.1m700.2m783.4m818.8m927.1m935.0m966.7m977.8m990.7m

Retained Earnings

(157.6m)(227.4m)(286.3m)(357.6m)(475.4m)(545.3m)(461.4m)(612.1m)(667.4m)(726.4m)(819.8m)(863.4m)(922.2m)(1.0b)(981.3m)(934.2m)

Total Equity

(152.0m)38.0m96.4m40.0m(66.9m)(61.9m)31.7m77.0m30.9m54.9m(3.1m)61.8m12.4m(38.5m)(4.0m)56.0m

Financial Leverage

-0.8 x4 x2.6 x5.1 x-3.4 x-4.1 x6.1 x3 x5.6 x3.5 x-41.6 x3 x11.4 x-4.8 x-60.3 x5.8 x

Coherus BioSciences Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(87.2m)(223.9m)(127.8m)(238.3m)(209.4m)89.8m

Depreciation and Amortization

674.0k3.0m3.4m3.2m

Accounts Receivable

1.9m(142.0m)

Inventories

(5.5m)(48.2m)

Accounts Payable

3.6m(5.0m)(3.8m)(301.0k)9.9m

Cash From Operating Activities

(23.9m)(252.5m)(200.3m)(159.3m)28.4m

Purchases of PP&E

(2.8m)(6.5m)(4.6m)(789.0k)(1.8m)

Cash From Investing Activities

(525.0k)(6.5m)(4.4m)(1.2m)(12.7m)

Dividends Paid

(116.0k)(2.1m)

Cash From Financing Activities

136.0m226.2m206.8m105.4m89.4m

Net Change in Cash

2.0m(54.6m)104.7m

Interest Paid

6.9m8.2m8.2m15.3m

Income Taxes Paid

1.7m

Coherus BioSciences Ratios

USDY, 2019

EV/EBIT

9.1 x

EV/CFO

34.6 x

Revenue/Employee

1.3m

Financial Leverage

3.9 x

Coherus BioSciences Employee Rating

4.628 votes
Culture & Values
4.5
Work/Life Balance
3.6
Senior Management
4.6
Salary & Benefits
4.4
Career Opportunities
4.6
Source